Pfizer Common Stock Dividends Paid 2010-2025 | PFE

Pfizer annual/quarterly common stock dividends paid history and growth rate from 2010 to 2025. Common stock dividends paid can be defined as the cash outflow for dividends paid on a company's common stock
  • Pfizer common stock dividends paid for the quarter ending June 30, 2025 were $-4.882B, a 2.74% increase year-over-year.
  • Pfizer common stock dividends paid for the twelve months ending June 30, 2025 were $-23.963B, a 2.83% increase year-over-year.
  • Pfizer annual common stock dividends paid for 2024 were $-9.512B, a 2.87% increase from 2023.
  • Pfizer annual common stock dividends paid for 2023 were $-9.247B, a 2.94% increase from 2022.
  • Pfizer annual common stock dividends paid for 2022 were $-8.983B, a 2.91% increase from 2021.
Pfizer Annual Common Stock Dividends Paid
(Millions of US $)
2024 $-9,512
2023 $-9,247
2022 $-8,983
2021 $-8,729
2020 $-8,440
2019 $-8,043
2018 $-7,978
2017 $-7,659
2016 $-7,317
2015 $-6,940
2014 $-6,609
2013 $-6,580
2012 $-6,534
2011 $-6,234
2010 $-6,088
2009 $-5,548
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $147.142B $63.627B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $673.574B 44.07
Johnson & Johnson (JNJ) United States $431.791B 17.93
AbbVie (ABBV) United States $372.037B 19.89
Novartis AG (NVS) Switzerland $268.235B 14.53
Roche Holding AG (RHHBY) Switzerland $260.064B 0.00
Novo Nordisk (NVO) Denmark $254.416B 15.40
Merck (MRK) United States $218.231B 11.44
Sanofi (SNY) France $126.091B 12.49
Bayer (BAYRY) Germany $32.695B 6.16
Innoviva (INVA) United States $1.270B 12.52